Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

Université de Montréal

$40,000.00

Vector and cell engineering to increase productivity and stability of recombinant protein production in CHO cells

EF 2011-12

Résumé
Biologics (proteins, antibodies and vaccines) account for a significant (7.5%) and increasing share (20% annual growth) of new therapeutics entering the clinic and the market, displacing the traditional small-molecule chemical compounds; 33% of all drugs currently in development are biologics (PharmaVision 2009. Delivering New Biopharmaceutical Therapies: Challenges & Opportunities). Together with vaccines and gene therapy products, therapeutic proteins represent half of the FDA-approved therapeutics in the pipeline. As a result, we are witnessing a spectacular emergence of biologics in the top 10 most selling drugs. In 2000, there was only one biologic in the top 10: erythropoietin. The forecast for 2014 indicated that there would be 7 biologics in the top 10: 5 humanized antibodies and 2 recombinant proteins (Biotech 2010 Live Sciences: Adapting for success, Burrill & Company). Hence, therapeutic antibodies and derivatives thereof have the lion's share of this market. In order to expand their applications, significant improvements are required to lower their production costs while improving their quality. Thus, it is estimated that the cost of production of therapeutic antibodies must be reduced by at least one order of magnitude in order to ensure economic viability of a significant proportion of the products currently in clinical trials. Therefore much remains to be done to improve the efficiency of high-producing clones generation and we will explore new vector and cell engineering strategies toward that goal.
Programme
Discovery Grants Program - Individual
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
298293-2011
Name nom
Massie, Bernard
Department département
Microbiologie et immunologie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
40000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
1
Nb partie
5
Application title
Vector and cell engineering to increase productivity and stability of recombinant protein production in CHO cells
Keyword
NSERC
Application summary
Biologics (proteins, antibodies and vaccines) account for a significant (7.5%) and increasing share (20% annual growth) of new therapeutics entering the clinic and the market, displacing the traditional small-molecule chemical compounds; 33% of all drugs currently in development are biologics (PharmaVision 2009. Delivering New Biopharmaceutical Therapies: Challenges & Opportunities). Together with vaccines and gene therapy products, therapeutic proteins represent half of the FDA-approved therapeutics in the pipeline. As a result, we are witnessing a spectacular emergence of biologics in the top 10 most selling drugs. In 2000, there was only one biologic in the top 10: erythropoietin. The forecast for 2014 indicated that there would be 7 biologics in the top 10: 5 humanized antibodies and 2 recombinant proteins (Biotech 2010 Live Sciences: Adapting for success, Burrill & Company). Hence, therapeutic antibodies and derivatives thereof have the lion's share of this market. In order to expand their applications, significant improvements are required to lower their production costs while improving their quality. Thus, it is estimated that the cost of production of therapeutic antibodies must be reduced by at least one order of magnitude in order to ensure economic viability of a significant proportion of the products currently in clinical trials. Therefore much remains to be done to improve the efficiency of high-producing clones generation and we will explore new vector and cell engineering strategies toward that goal.